- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00330460
A Randomized, Double-Blind Study to Compare the Efficacy of Treatment With Denosumab Versus Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density.
A Randomized, Double-Blind Study to Compare the Efficacy of Treatment With Denosumab Versus Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Denisty
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria: - Patient is an ambulatory postmenopausal woman - Patient has BMD value that corresponds to a T-score of less than or equal to -2.0 (g/cm2) at the lumbar spine OR total hip within range specific to the study protocol. Exclusion Criteria: o Any disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures
Evidence of any of the following per subject report, chart review or central laboratory result:
Hyper- or hypothyroidism; however, subjects on stable thyroid hormone replacement therapy may be allowed per the following criteria:
- If TSH level is normal, subject is eligible for the study.
- If TSH level is below normal range, subject is not eligible for the study.
- If TSH level is elevated (> 5.5 mIU/mL to 10.0 mIU/mL), serum T4 should be measured. If serum T4 is within normal range, subject is eligible. If serum T4 is outside of normal range, subject is not eligible for the study.
- If TSH level is above 10.0 mIU/mL, subject is not eligible.
- Current hyper- or hypoparathyroidism
Elevated transaminases
- Serum aspartate aminotransferase (AST; serum glutamate-oxaloacetic transaminase [SGOT]) ³ 2.0 x upper limits of normal (ULN)
- Serum alanine aminotransferase (ALT; serum glutamate-pyruvate transaminase [SGPT]) ³ 2.0 x ULN
- Significantly impaired renal function as determined by serum creatinine ³ 2.0 mg/dL
- Current hypo- or hypercalcemia based on the central laboratory reference ranges
- Active gastric or duodenal ulcer; history of significant gastrointestinal bleed requiring hospitalization or transfusion, or dyspepsia or gastroesophageal reflux disease that is uncontrolled by medication
- Rheumatoid Arthritis, Paget's disease, Cushing's disease, hyperprolactinemia, or cirrhosis of the liver
- Known to have tested positive for human immunodeficiency virus, hepatitis C virus, or hepatitis B surface antigen
- Malignancy (except fully resected cutaneous basal cell or squamous cell carcinoma, cervical or breast ductal carcinoma in situ) within the last 5 years
- Any metabolic bone disease, eg, osteomalacia or osteogenesis imperfecta, which may interfere with the interpretation of the findings
- Malabsorption syndrome or any gastrointestinal disorders that are associated with malabsorption
- Received any solid organ or bone marrow transplant
- Vitamin D deficiency (25(OH) vitamin D level < 12 ng/mL). Vitamin D repletion will be permitted and subjects may be re-screened; see Section 7.
- Any laboratory abnormality which, in the opinion of the investigator, will prevent the subject from completing the study or interfere with the interpretation of the study results
Contraindicated or poorly tolerant of ALN therapy; contraindications for ALN therapy include:
- Abnormalities of the esophagus, which delay esophageal emptying such as stricture or achalasia.
- Inability to stand or sit upright for at least 30 minutes.
- Hypersensitivity to ALN or other constituents of ALN tablets o Known sensitivity to mammalian cell derived drug products
- Known intolerance to calcium supplements
- Administration of intravenous bisphosphonate, or fluoride (except for dental treatment) or strontium ranelate
Oral bisphosphonate treatment:
- ³ 3 months cumulatively in the past 2 years, OR
- ³ 1 month in the past year, OR
- Any use during the 3-month period prior to randomization
- PTH or PTH derivatives (eg, teriparatide) within the last year
Administration of any of the following treatments within 3 months of randomization:
- Any SERM (eg, raloxifene)
- Tibolone
- Anabolic steroids or testosterone
- Glucocorticosteroids (³ 5 mg prednisone equivalent per day for more than 10 days)
- Systemic (oral, transdermal, topical) hormone replacement therapy (local vaginal estrogen preparation will be allowed)
- Calcitonin
- Calcitriol or vitamin D derivatives
- Other bone active drugs including anti-convulsives (except benzodiazepines) and heparin
- Chronic systemic ketoconazole, androgens, ACTH, cinacalcet, aluminum, lithium, protease inhibitors, methotrexate, gonadotropin-releasing hormone agonists
- Height, weight or girth which may preclude accurate DXA measurements
- Less than 2 lumbar vertebrae (L1-L4) evaluable for DXA measurements
- Both hips not evaluable by DXA (eg, history of bilateral hip replacement or pins in both hips)
- Currently enrolled in or has not yet completed at least 1 month since ending other investigational device or drug trial(s), or subject is receiving other investigational agent(s)
- Any physical or psychiatric disorder which, in the opinion of the investigator, will prevent the subject from completing the study or interfere with the interpretation of the study results
- Evidence of alcohol or substance-abuse within the last 12 months which the investigator believes would interfere with understanding or completing the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Alendronate
Subjects in this arm will receive active ALN and placebo denosumab
|
ALN; 70 mg; oral; once weekly
|
Experimental: Denosumab
Subjects in this arm will receive active denosumab and placbo ALN
|
60 mg; SC; every 6 months
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total Hip Bone Mineral Density Percent Change From Baseline at Month 12
Time Frame: 12 months
|
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12
Time Frame: 12 months
|
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.
|
12 months
|
Trochanter Bone Mineral Density Percent Change From Baseline at Month 12
Time Frame: 12 months
|
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.
|
12 months
|
Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 12
Time Frame: 12 months
|
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.
|
12 months
|
Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 12
Time Frame: 12 months
|
Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.
|
12 months
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Gold DT, Horne R, Coon CD, Price MA, Borenstein J, Varon SF, Satram-Hoang S, Macarios D. Development, reliability, and validity of a new Preference and Satisfaction Questionnaire. Value Health. 2011 Dec;14(8):1109-16. doi: 10.1016/j.jval.2011.06.010. Epub 2011 Oct 1.
- Brown JP, Prince RL, Deal C, Recker RR, Kiel DP, de Gregorio LH, Hadji P, Hofbauer LC, Alvaro-Gracia JM, Wang H, Austin M, Wagman RB, Newmark R, Libanati C, San Martin J, Bone HG. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res. 2009 Jan;24(1):153-61. doi: 10.1359/jbmr.0809010.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20050141
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoporosis
-
Radius Health, Inc.CompletedOsteoporosis | Osteoporosis Risk | Osteoporosis, Postmenopausal | Osteoporosis Fracture | Osteoporosis, Age-Related | Osteoporosis Localized to Spine | Osteoporosis Senile | Osteoporosis of Vertebrae | Osteoporosis VertebralUnited States
-
Radius Health, Inc.CompletedOsteoporosis | Age Related Osteoporosis | Osteoporosis, Age-Related | Osteoporosis Localized to Spine | Osteoporosis Senile | Osteoporosis of VertebraeUnited States, Poland, Italy
-
Hoffmann-La RocheCompletedPostmenopausal OsteoporosisUnited States
-
Hoffmann-La RocheCompletedPost Menopausal OsteoporosisUnited States, Puerto Rico
-
Centre Hospitalier Universitaire de Saint EtienneMinistry of Health, FranceRecruitingPost Menopausal OsteoporosisFrance
-
AmgenCompletedPost Menopausal OsteoporosisFrance
-
Hoffmann-La RocheCompletedPost Menopausal OsteoporosisUnited States
-
Hoffmann-La RocheCompletedPost Menopausal OsteoporosisSpain, South Africa, Germany, Mexico, United States, Canada, France, United Kingdom, Italy, Belgium, Australia, Poland, Denmark, Hungary, Czech Republic, Norway
-
Hoffmann-La RocheGlaxoSmithKlineCompletedPost Menopausal OsteoporosisFrance
-
Novartis PharmaceuticalsCompletedPost-menopausal OsteoporosisColombia, Belgium, Sweden, Hong Kong, United States, Hungary, Switzerland, Australia, Germany, Italy, Canada, Poland, Argentina, Thailand, Norway, New Zealand, France, Finland
Clinical Trials on Alendronate
-
University of California, DavisNational Heart, Lung, and Blood Institute (NHLBI); Doris Duke Charitable FoundationNot yet recruitingOsteonecrosis | Avascular Necrosis | Sickle Cell Disease | Sickle Cell Anemia | Ischemic Necrosis
-
Aarhus University HospitalCompleted
-
Shanghai JMT-Bio Inc.Not yet recruitingGlucocorticoid Induced OsteoporosisChina
-
Göteborg UniversityCompletedOsteoporosis | Ankylosing SpondylitisSweden
-
National Institute of Diabetes and Digestive and...CompletedProstate Cancer | Osteoporosis | HypogonadismUnited States
-
National Taiwan University HospitalCompletedOsteoporosis | End-Stage Renal Disease
-
Chinese University of Hong KongRecruitingACL ReconstructionHong Kong
-
Aarhus University HospitalUniversity of AarhusCompleted
-
National Institute of Dental and Craniofacial Research...CompletedPolyostotic Fibrous DysplasiaUnited States
-
Ciudad Universitaria, SpainCompleted